PALATIN'S PT-141 INCREASES SEXUAL BEHAVIOR IN FEMALE ANIMALS.
The studies' objectives were to evaluate PT-141's ability to enhance sexual behavior in female rodents. The studies were designed to allow for the evaluation of PT-141's effect on a variety of normal precopulatory sexual behaviors that are used by female rodents to heighten sexual arousal in their male partners. Female animals given PT-141 showed a significant, dose-responsive increase in a variety of these precopulatory sexual behaviors and actively solicited sexual contact from the males. Importantly, PT-141 treatment increased the female rodents' desire to copulate.
"These data suggest that stimulation of melanocortin receptors in the brain by PT-141 selectively increased motivation for sexual activity in female rodents. The results indicate that PT-141 has potential to offer a unique treatment for women with desire disorders," said Dr. Annette Shadiack, Ph.D, director, Biological Research at Palatin.
Perry Molinoff, M.D., executive vice president of Research & Development of Palatin said, "We are very excited about these results, which, in combination with the positive safety results from our Phase 1 clinical study in men, provide the basis for advancing this investigational drug into Phase 2 efficacy trials in women with Female Sexual Dysfunction (FSD) early next year."
Palatin recently completed a Phase 1 safety trial with PT-141 in men that demonstrated a positive safety profile. PT-141 was well tolerated at all doses, there were no significant changes in blood pressure, heart rate or respiration rate, and investigators reported no serious side effects. A Phase 2A efficacy study of patients with erectile dysfunction is scheduled to begin later this year.
PT-141 is a peptide analog of the neuropeptide hormone (alpha)-MSH ((alpha)-melanocyte-stimulating hormone). Scientists have determined that receptors for this class of molecules (melanocortin receptors) play a role in several behaviors including appetite and sexual arousal. Recent findings indicate the effects on sexual function may be stimulated through melanocortin receptors in the brain. As a result, Palatin believes PT-141 has the potential to offer a unique treatment for both male and female sexual dysfunction.
Palatin Technologies, Inc. is a development-stage biopharmaceutical company. The company is currently conducting clinical investigations with its lead drug, PT-141, for the treatment of erectile dysfunction, and is developing additional therapeutic compounds discovered using its enabling peptide platform technology, MIDAS. Additionally, Palatin is developing a product for infection imaging, LeuTech(R), based on a proprietary radiolabeled monoclonal antibody.
For more information, visit http://www.palatin.com or call 609/520-1911.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 1, 2001|
|Previous Article:||NAPRO GETS NEW PACLITAXEL FORMULATION PATENT.|
|Next Article:||AGENCOURT COMPLETES DNA SEQUENCING PROJECT FOR WHITEHEAD.|